[1] |
庄心良,曾因明,陈伯銮.现代麻醉学. 3版.北京:人民卫生出版社, 2004: 562-589.
|
[2] |
Tran TV,Fiset P,Varin F. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. Anesth Analg, 1998, 87(5): 1158-1163.
|
[3] |
Bergeron L,Bevan DR,Berrill A, et al. Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology, 2001, 95(2): 314-323.
|
[4] |
Meretoja O. Update on muscle relaxants. Paediatr Anaesth, 2004, 14(5): 384-386.
|
[5] |
邹宗强,孟凡民.顺式阿曲库铵用于肝硬化患者全凭静脉麻醉的肌松效应.山东医药, 2009, 49(16): 53-54.
|
[6] |
殷国平,胡万进,张维峰,等.麻醉方法对肝炎肝硬化手术患者免疫功能的影响.江苏医药, 2013, 39(11): 1284-1286.
|
[7] |
朱宇麟,景桂霞,赵鸽,等.顺苯磺酸阿曲库铵在肝移植患者应用中的肌松效果及安全性.广东医学, 2009, 30(4): 588-589.
|
[8] |
崔春吉.终末期肝病模型在评估肝硬化患者预后中的价值.世界华人消化杂志, 2010, 18(22): 2375-2378.
|
[9] |
Cooper R,Mirakhur RK,Clarke RS, et al. Comparison of intubating conditions after administration of Org 9246 (rocuronium) and suxamethonium. Br J Anaesth, 1992, 69(3): 269-273.
|
[10] |
Benedeto-Stojanov D,Nagorni A,Bjelakovic G, et al. The model for the end-stage liver disease and Child-Pugh score in predicting prognosis in patients with liver cirrhosis and esophageal variceal bleeding. Vojnosanit Pregl, 2009, 66(9): 724-728.
|
[11] |
李灵敏,肖天利,陈文生. MELD与CTP评分系统对TIPS术后患者预后的评价作用.第三军医大学学报, 2009, 31(8): 733-736.
|
[12] |
Soubhia AF,Lauz S,Montero EF, et al. Effects of the inhalational anesthetics halothane and sevoflurane on an experimental model of hepatic injury. Rev Bras Anestesiol, 2011, 61(5): 324-330, 591-603.
|
[13] |
Alotaibi WM. Severe hepatic dysfunction after sevoflurane exposure. Saudi Med J, 2008, 29(9): 1344-1346.
|
[14] |
邬子林,佘守章,许立新,等.腹部手术中慢性肝功能不全病人罗库溴铵的药效学.中华麻醉学杂志, 2005, 25(9): 653-656.
|
[15] |
周洁,齐波,王祥瑞,等.肝功能不全门脉高压病人罗库溴铵的肌松效应.中华麻醉学杂志, 2004, 24(8): 585-587.
|
[16] |
Kisor DF,Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet, 1999, 36(1): 27-40.
|